Postdoctoral Researcher in Vascular/Cancer Biology at the University of Helsinki2.4.2019
The University of Helsinki is an international scientific community of 40,000 students and researchers, and ranks among the top 100 international universities in the world.
Research Programs Unit (RPU) of the Faculty of Medicine, University of Helsinki (https://www.helsinki.fi/en/faculty-of-medicine/research-programs-unit) consolidates demonstrated research excellence, with nine focused research programs combining clinical, translational and biomedical research.
The group of Associate Professor Pipsa Saharinen works on the molecular and cellular mechanisms that regulate blood vessel functions during inflammation and in cancer (www.helsinki.fi/saharinenlab). A special focus is on the dynamic regulation of vascular permeability by angiopoietin growth factor, cytokine and integrin adhesion receptor signalling. The group is funded by the European Research Council (ERC) and belongs to the Academy of Finland Centre of Excellence in Translational Cancer Biology.
The Saharinen group is currently seeking for a
for a fixed-term starting as soon as possible, upon mutual agreement.
Highly motivated individuals with a commitment to excellence and with the capability to work independently and as a part of a dynamic and collaborative research group are encouraged to apply. A PhD degree in Life or Biomedical sciences, or an MD PhD degree, as well as excellent communication skills in spoken and written English, are required. Strong background in vascular/cancer biology, imaging, mouse genetics, or cell/molecular biology is an advantage.
We offer an international, inspiring and supportive research environment, excellent research facilities with access to state-of-the art technologies and a competitive salary, which is comprised of two separate parts; the job requirement component (here, level 5) and the personal performance component based on previous qualifications, experience and personal work performance, as per defined in the General Collective Agreement for Finnish Universities. A six-month trial period will be applied.
The application should include the following documents as a single pdf-file: a cover letter describing previous achievements and motivation for the position (1 page), CV, track record of peer-reviewed publications, and names and contact details of two to three referees. To apply, please, go to
Apply by 15.4.2019. The position will be filled once a suitable candidate has been identified. Further information is available from Pipsa.Saharinen(a)Helsinki.fi, tel. +358-50-4486361.
Hakanpaa et al., Targeting beta1-integrin inhibits vascular leakage in endotoxemia. Proc Natl Acad Sci USA. 115:E6467-E6476, 2018.
Korhonen E, Lampinen A et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. 126: 3495-3510, 2016.
Hakanpaa et al. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nature Commun 6: 5962, 2015.
Saharinen et al., Therapeutic targeting of the angiopoietin–TIE pathway. Nat. Rev. Drug. Disc. 16:635-661, 2017.
Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signaling in the cardiovascular and lymphatic systems. Clin. Science. 1:87-103, 2017.